|
Delayed
NSE India S.E.
11:07:43 19/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 1,889.40 INR | +0.76% |
|
-2.67% | +10.02% |
| 08-05 | CRISIL Keeps AAA Rating on Sun Pharmaceutical's Bank Facilities | MT |
| 07-31 | Sun Pharmaceutical Industries Limited, Q1 2027 Earnings Call, Jul 31, 2026 |
| Market Cap | 4,499B 46.96B 40.56B 38.16B 34.68B 65.23B 66.18B 448B 175B 2,250B 176B 172B 7,495B | P/E 2027 * |
34.6x | P/E 2028 * | 29.3x |
|---|---|---|---|---|---|
| Enterprise Value | 4,220B 44.04B 38.04B 35.79B 32.53B 61.18B 62.08B 420B 165B 2,111B 165B 162B 7,030B | EV / Sales 2027 * |
6.48x | EV / Sales 2028 * | 5.69x |
| Free-Float |
44.39% | Yield 2027 * |
0.91% | Yield 2028 * | 1.06% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | +0.90% | ||
| 1 week | -2.67% | ||
| Current month | -4.95% | ||
| 1 month | -3.29% | ||
| 3 months | +0.52% | ||
| 6 months | +10.42% | ||
| Current year | +10.02% |
| 1 week | 1,868.3 |  | 1,949.8 |
| 1 month | 1,868.3 | | 2,046.9 |
| Current year | 1,583.7 | | 2,046.9 |
| 1 year | 1,548 | | 2,046.9 |
| 3 years | 1,068.35 | | 2,046.9 |
| 5 years | 733.7 | | 2,046.9 |
| 10 years | 312 | | 2,046.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | -2.67% | +16.32% | +66.34% | 46.96B | |
| +0.12% | -1.59% | +47.86% | +123.16% | 39.63B | |
| -0.74% | -2.89% | -8.28% | +15.15% | 12.07B | |
| -0.27% | -7.66% | +12.46% | +70.37% | 11.61B | |
| +0.58% | 0.00% | +30.65% | +147.62% | 9.11B | |
| +0.23% | -0.69% | +20.48% | +40.20% | 7.47B | |
| +0.80% | +1.82% | +43.27% | -11.49% | 7.18B | |
| -2.68% | -2.11% | +15.20% | +189.22% | 6.79B | |
| -0.97% | -2.30% | -30.37% | +24.93% | 5.75B | |
| -0.78% | +3.85% | +36.03% | +105.50% | 4.83B | |
| Average | -0.30% | +0.04% | +18.36% | +77.10% | 15.14B | |
| Weighted average by Cap. | +0.12% | -1.89% | +23.47% | +82.54% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 651B 6.79B 5.87B 5.52B 5.02B 9.44B 9.58B 64.76B 25.38B 326B 25.51B 24.95B 1,084B | 729B 7.61B 6.57B 6.18B 5.62B 10.57B 10.72B 72.5B 28.41B 364B 28.55B 27.93B 1,214B |
| Net income | 130B 1.36B 1.17B 1.1B 1B 1.89B 1.91B 12.95B 5.07B 65.09B 5.1B 4.99B 217B | 154B 1.61B 1.39B 1.31B 1.19B 2.24B 2.27B 15.34B 6.01B 77.12B 6.04B 5.91B 257B |
| Net Debt | -279B -2.91B -2.52B -2.37B -2.15B -4.05B -4.1B -27.76B -10.88B -140B -10.93B -10.7B -465B | -349B -3.64B -3.15B -2.96B -2.69B -5.06B -5.14B -34.74B -13.61B -175B -13.68B -13.39B -582B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/08/26 | ₹1,889.40 | +0.76% | 673,364 |
| 18/08/26 | ₹1,875.10 | -0.37% | 1,819,169 |
| 17/08/26 | ₹1,882.00 | -2.49% | 1,893,086 |
| 14/08/26 | ₹1,930.00 | -0.10% | 881,282 |
| 13/08/26 | ₹1,932.00 | -0.62% | 1,216,049 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
